Patents by Inventor Glenn J. Bubley

Glenn J. Bubley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Drug complex for treatment of metastatic prostate cancer
    Publication number: 20030035804
    Abstract: A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the specific cell type; a linker which is acted upon by a molecule which is present at an effective concentration in the environs of the specific cell type; and a drug or an agent to be delivered to the specific cell type. In particular, a drug complex for delivering a cytotoxic drug to prostate cancer cells, comprising a targeting carrier molecule which is selectively delivered to prostate tissue, bone or both; a peptide which is a substrate for prostate specific antigen; and a cytotoxic drug which is toxic to androgen independent prostate cancer cells.
    Type: Application
    Filed: April 9, 2002
    Publication date: February 20, 2003
    Applicant: Beth Israel Deaconess Medical Center
    Inventors: Anthony V. D'Amico, Glenn J. Bubley, David J. Jebaratnam, James S. Weinberg
  • Drug complex for treatment of metastatic prostate cancer
    Patent number: 6368598
    Abstract: A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the specific cell type; a linker which is acted upon by a molecule which is present at an effective concentration in the environs of the specific cell type; and a drug or an agent to be delivered to the specific cell type. In particular, a drug complex for delivering a cytotoxic drug to prostate cancer cells, comprising a targeting carrier molecule which is selectively delivered to prostate tissue, bone or both; a peptide which is a substrate for prostate specific antigen; and a cytotoxic drug which is toxic to androgen independent prostate cancer cells.
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: April 9, 2002
    Assignee: JCRT Radiation Oncology Support Services, Inc.
    Inventors: Anthony V. D'Amico, Glenn J. Bubley, David J. Jebaratnam, James S. Weinberg